A 2022 inventory in oncology news

The Cancer Bulletin continues its tradition. At the beginning of 2023, the members of the editorial committee would like to share with you their analyses of the highlights of 2022. The objective remains to highlight what will change our practices and lead to different diagnostic or therapeutic options. Our synthesis will therefore focus on published data. They have been analyzed and placed in the more general context of the management of each type of cancer to deduce the practical consequences for our patients. This synthesis exercise will concern almost all tumor pathologies, most often on the therapeutic level, and will, however, exclude the evolution of techniques, whether they are diagnostic or used for the follow-up of our patients. The final objective is to allow you to have a thoughtful, didactic and practical reading. Our goal is to provide our readers with the rational bases that can lead to a different approach for treatments in 2023.

Automated summary

This article presents the analysis of highlights from 2022 by the editorial committee members of The Cancer Bulletin. Their objective is to provide readers with a thoughtful, educational, and practical reading by analyzing published data and placing it in the context of cancer management. The goal is to offer rational bases for different treatment approaches in 2023.